09/02/2026
💭 Spravato and ketamine therapy are becoming increasingly visible in mental health care, but they aren’t interchangeable, and understanding the differences matters.
Spravato (esketamine) has specific FDA-approved uses for depression and is administered in certified healthcare settings with required monitoring. Ketamine itself is FDA-approved as an anesthetic and may be used off-label for psychiatric conditions. Compounded and at-home ketamine products can involve different levels of oversight.
While ketamine-based treatment may provide meaningful benefits for appropriately selected individuals, ketamine also has recognized abuse and dependence potential. Warning signs of problematic use can include increasing doses or frequency, cravings, hiding use, seeking dissociation, or continuing despite negative consequences.
Our latest article explores:
• Spravato vs. ketamine therapy
• Why these treatments are used for depression
• FDA-approved, off-label, and compounded products
• Why Spravato requires monitoring
• Ketamine misuse, dependence, and addiction concerns
• Dissociation and “K-holes”
• Ketamine bladder syndrome and “K-cramps”
• Ketamine use and chronic pain
• At-home ketamine considerations
• Warning signs that ketamine use may be becoming a problem
• Treating depression and substance use together
💚 The conversation around ketamine shouldn’t be reduced to “good” or “bad.” Understanding the treatment, its purpose, its safeguards, and its risks can help individuals make more informed decisions about their mental health.
👉 Read the full article:
https://bit.ly/4xA5IMJ